Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Low hepcidin triggers hepatic iron accumulation in patients with hepatitis C.

Hörl WH, Schmidt A.

Nephrol Dial Transplant. 2014 Jun;29(6):1141-4. doi: 10.1093/ndt/gft467. Epub 2013 Nov 27.

PMID:
24286977
2.

Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion.

Fujita N, Sugimoto R, Motonishi S, Tomosugi N, Tanaka H, Takeo M, Iwasa M, Kobayashi Y, Hayashi H, Kaito M, Takei Y.

J Hepatol. 2008 Nov;49(5):702-10. doi: 10.1016/j.jhep.2008.05.014. Epub 2008 Jun 6.

PMID:
18620776
3.

Pegylated interferon-α induced hypoferremia is associated with the immediate response to treatment in hepatitis C.

Ryan JD, Altamura S, Devitt E, Mullins S, Lawless MW, Muckenthaler MU, Crowe J.

Hepatology. 2012 Aug;56(2):492-500. doi: 10.1002/hep.25666. Epub 2012 Jun 11.

PMID:
22334511
4.

Reduced serum hepcidin levels in patients with chronic hepatitis C.

Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A, Busti F, Campostrini N, Martinelli N, Vantini I, Corrocher R, Ganz T, Fattovich G.

J Hepatol. 2009 Nov;51(5):845-52. doi: 10.1016/j.jhep.2009.06.027. Epub 2009 Aug 12.

5.

Association of hepatic oxidative stress and iron dysregulation with HCC development after interferon therapy in chronic hepatitis C.

Nanba S, Ikeda F, Baba N, Takaguchi K, Senoh T, Nagano T, Seki H, Takeuchi Y, Moritou Y, Yasunaka T, Ohnishi H, Miyake Y, Takaki A, Nouso K, Iwasaki Y, Yamamoto K.

J Clin Pathol. 2016 Mar;69(3):226-33. doi: 10.1136/jclinpath-2015-203215. Epub 2015 Aug 19.

PMID:
26290259
6.

The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment of chronic hepatitis C.

Sikorska K, Stalke P, Izycka-Swieszewska E, Romanowski T, Bielawski KP.

Med Sci Monit. 2010 Mar;16(3):CR137-143.

PMID:
20190684
7.

Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.

Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, Kobayashi Y, Iwasa M, Watanabe S, Adachi Y, Kaito M.

Mol Med. 2007 Jan-Feb;13(1-2):97-104.

8.

Hepcidin levels and iron status in beta-thalassemia major patients with hepatitis C virus infection.

Hendy OM, Allam M, Allam A, Attia MH, El Taher S, Eldin MM, Ali A.

Egypt J Immunol. 2010;17(2):33-44.

PMID:
23082485
9.

Iron overload and glucose abnormalities in chronic hepatitis C virus infection: phlebotomy lowers risk of new-onset diabetes.

Mifuji-Moroka R, Iwasa M, Miyachi H, Sugimoto R, Tanaka H, Ishihara T, Fujita N, Kaito M, Kobayashi Y, Takei Y.

Hepatogastroenterology. 2013 Oct;60(127):1736-41.

PMID:
24634944
10.

Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription.

Nishina S, Hino K, Korenaga M, Vecchi C, Pietrangelo A, Mizukami Y, Furutani T, Sakai A, Okuda M, Hidaka I, Okita K, Sakaida I.

Gastroenterology. 2008 Jan;134(1):226-38. doi: 10.1053/j.gastro.2007.10.011. Epub 2007 Oct 9.

PMID:
18166355
11.

Iron regulator hepcidin exhibits antiviral activity against hepatitis C virus.

Liu H, Trinh TL, Dong H, Keith R, Nelson D, Liu C.

PLoS One. 2012;7(10):e46631. doi: 10.1371/journal.pone.0046631. Epub 2012 Oct 22.

12.

Alterations in the iron homeostasis network: A driving force for macrophage-mediated hepatitis C virus persistency.

Foka P, Dimitriadis A, Karamichali E, Kyratzopoulou E, Giannimaras D, Koskinas J, Varaklioti A, Mamalaki A, Georgopoulou U.

Virulence. 2016 Aug 17;7(6):679-90. doi: 10.1080/21505594.2016.1175700. Epub 2016 Apr 8.

13.

Ribavirin in the treatment of hepatitis C.

Abonyi ME, Lakatos PL.

Anticancer Res. 2005 Mar-Apr;25(2B):1315-20.

14.

Treatment of chronic hepatitis C in Asia: when East meets West.

Yu ML, Chuang WL.

J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x. Review.

PMID:
19335784
15.

Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients.

Fujita N, Horiike S, Sugimoto R, Tanaka H, Iwasa M, Kobayashi Y, Hasegawa K, Ma N, Kawanishi S, Adachi Y, Kaito M.

Free Radic Biol Med. 2007 Feb 1;42(3):353-62. Epub 2006 Nov 6.

PMID:
17210448
16.

Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C.

Kamar N, Boulestin A, Selves J, Esposito L, Sandres-Saune K, Stébenet M, Chatelut E, Durand D, Rostaing L, Izopet J.

J Med Virol. 2005 May;76(1):61-8.

PMID:
15778976
17.

Treatment of chronic hepatitis C virus infection in patients with cirrhosis.

Zeuzem S.

J Viral Hepat. 2000 Sep;7(5):327-34. Review.

PMID:
10971820
18.

Role of iron in the natural history and clinical course of hepatitis C disease.

Shedlofsky SI.

Hepatogastroenterology. 1998 Mar-Apr;45(20):349-55. Review.

PMID:
9638405
19.

Association of hepcidin mRNA expression with hepatocyte iron accumulation and effects of antiviral therapy in chronic hepatitis C infection.

Sikorska K, Romanowski T, Stalke P, Izycka Swieszewska E, Bielawski KP.

Hepat Mon. 2014 Nov 1;14(11):e21184. doi: 10.5812/hepatmon.21184. eCollection 2014 Nov.

20.

Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C.

Tsochatzis E, Papatheodoridis GV, Koliaraki V, Hadziyannis E, Kafiri G, Manesis EK, Mamalaki A, Archimandritis AJ.

J Viral Hepat. 2010 Nov;17(11):800-6. doi: 10.1111/j.1365-2893.2009.01244.x.

PMID:
20002304

Supplemental Content

Support Center